Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

by @JTC_PALIdev | Feb 10, 2025 | Press Releases

Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a...

Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress

by @JTC_PALIdev | Jan 29, 2025 | Press Releases

Carlsbad, CA, Jan. 29, 2025 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients...

Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

by @JTC_PALIdev | Jan 22, 2025 | Press Releases

Live webcast on Wednesday, January 29th at 2:20 PM ET Carlsbad, CA, Jan. 22, 2025 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on...

Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis

by @JTC_PALIdev | Jan 16, 2025 | Press Releases

Company on track to report topline data in first half of 2025 Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of PALI-2108 Continued progress toward Phase 1b/2a of PALI-2108 trial...

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

by @JTC_PALIdev | Jan 3, 2025 | Press Releases

Carlsbad, CA, Jan. 03, 2025 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients...